Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This genome-wide association study identified several genetic markers, including specific SNPs and HLA genotypes, associated with alopecia areata susceptibility in the Taiwanese population, highlighting key pathways involved in immune response and offering insights into the genetic origins of this autoimmune condition.

This study provides evidence that innate lymphoid cells-type 1 can induce alopecia areata in human hair follicles, challenging the view that it is solely a CD8+ T cell-driven autoimmune disease.

COVID-19 can cause various skin issues, including rashes and 'COVID toes', and may worsen autoimmune diseases or affect men with baldness more severely.

CD8+ T cells attack hair follicle stem cells, causing scarring and hair loss in Discoid Lupus.

In this case report, researchers documented a 71-year-old woman with both alopecia areata and bullous pemphigoid who showed significant improvement using dupilumab after other treatments failed, highlighting its potential for autoimmune diseases with overlapping inflammatory mechanisms.

Alopecia areata is an autoimmune disorder causing hair loss, linked to specific hair follicle antigens and genetic factors.

This study emphasizes the importance of early diagnosis and a collaborative healthcare team in managing Sjogren’s Disease due to its complex nature and symptom variability, highlighting that timely treatment is crucial to prevent further damage.

This review discusses recent advances in understanding alopecia areata's disease mechanisms and highlights JAK molecules as promising therapeutic targets, but reports no new clinical results; controlled trials are needed.

This review discusses case reports of autoimmune diseases following vaccination and the challenges of establishing a clear epidemiological connection, urging further investigation into vaccine-induced autoimmunity.

This review discusses the potential of JAK inhibitors as a promising treatment strategy for alopecia areata, highlighting their mechanism and recent FDA approval based on clinical trial efficacy.

This article discusses diffuse alopecia areata, highlighting its autoimmune characteristics, more intense inflammation, and challenges in diagnosis, but presents no new clinical findings.

This review discusses the potential of PRP treatment for alopecia areata, highlighting reported hair growth improvements but notes the need for randomized clinical trials to confirm efficacy.

This study found that human γδTregs promoted hair regrowth and restored hair follicle immune privilege in a model of alopecia areata, suggesting potential for cell-based therapy in autoimmune diseases.

In this study, researchers found that alopecia areata patients show a significant reduction in suppressive regulatory T-cells and an increase in inflammatory T-cell populations, suggesting an immunological imbalance contributing to the disease.

In this veterinary study, uveodermatological syndrome in dogs was reported to cause skin depigmentation, alopecia, and eye issues such as granulomatous panuveitis, which leads to complications like cataracts and glaucoma; while immunosuppressive therapy often helps, recurrence and treatment side effects challenging therapeutic management.

This review discusses the role of JAK inhibitors in treating atopic dermatitis, alopecia areata, and vitiligo, highlighting their effectiveness and safety considerations but stressing the need for further research on long-term safety and patient selection.

This study identified key genetic regions associated with alopecia areata, highlighting both acquired and innate immune involvement, with a novel link to the upregulation of ULBP ligands in autoimmune disease.

In this study, researchers found that quiescent stem cells resist immune attack due to downregulated antigen presentation, which may help explain the immune evasion of early cancer-initiating cells.

This study found that human dermal γδT-cells can act as stress sentinels and potentially trigger autoimmune responses toward stressed hair follicles, resembling features of alopecia areata.

This research highlights that JAK inhibitors, such as baricitinib, may effectively reverse symptoms of alopecia areata by targeting specific immune pathways, though safety and efficacy require further investigation.

This case study reports successful treatment of a 19-year-old with Satoyoshi syndrome using a combination of carbamazepine, methotrexate, prednisolone, and sex-steroids, improving muscle spasms, alopecia, and quality of life.

This review discusses the evolution of alopecia areata treatments towards more targeted therapies and reports no new clinical results, emphasizing cooperation between clinicians and scientists in understanding the disease's pathophysiology.

JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.

This study found that direct immunofluorescence of hair is a simple and non-invasive alternative for monitoring pemphigus vulgaris, matching skin biopsy results in the cases observed.

This review discusses current and potential approaches using stem cells for treating hypopigmentation disorders like vitiligo but does not present new clinical findings.

In this study, a five-year-old Labrador with pemphigus, characterized by erythematous lesions and confirmed through cytology, was successfully treated with a six-week regimen of oral immunosuppressive azathioprine and supportive medications, resulting in total recovery.

This case report describes perifollicular melanocyte regeneration in the affected skin of a patient with bullous pemphigoid, highlighting an underreported aspect of the condition in skin of color patients, and emphasizing the need for increased awareness and earlier diagnosis in this demographic.

This case report describes a 22-month-old with alopecia universalis who showed improved hair growth after receiving combination therapy with minoxidil, corticosteroids, and excimer laser.

This report describes a severe COVID-19 case in a patient with SLE and nephritis, where hydroxychloroquine improved outcomes after regular use.

This case report describes a patient with SLE and COVID-19, where hydroxychloroquine showed a favorable impact on the virus when taken regularly, leading to clinical improvement and discharge after 24 days.